Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
99 hedge funds and large institutions have $1.03B invested in Apellis Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 47 increasing their positions, 20 reducing their positions, and 13 closing their positions.
135% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 20
69% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 13
31% more capital invested
Capital invested by funds: $782M → $1.03B (+$243M)
8% more funds holding
Funds holding: 92 → 99 (+7)
0% more call options, than puts
Call options by funds: $1.91M | Put options by funds: $1.9M
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
7.28% less ownership
Funds ownership: 71.28% → 64% (-7.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$25.8M |
| 2 |
BlackRock
New York
|
+$15.9M |
| 3 |
State Street
Boston,
Massachusetts
|
+$12.7M |
| 4 |
Jennison Associates
New York
|
+$6.83M |
| 5 |
Goldman Sachs
New York
|
+$4.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$25.2M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$12.9M |
| 3 |
VP
venBio Partners
San Francisco,
California
|
-$10.7M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
-$7.11M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$6.17M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AG
101
Artal Group
Luxembourg
| – | -$5.85M | -300,000 | Closed |
|
|
OM
102
Opaleye Management
Boston,
Massachusetts
| – | -$2.24M | -115,000 | Closed |
|
|
MCM
103
Moore Capital Management
New York
| – | -$985K | -50,527 | Closed |
|
|
MIM
104
Monashee Investment Management
Boston,
Massachusetts
| – | -$852K | -43,700 | Closed |
|
105
Renaissance Technologies
New York
| – | -$511K | -26,200 | Closed |
|
|
EMG
106
Ellington Management Group
Old Greenwich,
Connecticut
| – | -$246K | -12,600 | Closed |
|
107
Voloridge Investment Management
Jupiter,
Florida
| – | -$230K | -11,798 | Closed |
|
|
SCA
108
Secor Capital Advisors
New York
| – | -$211K | -10,834 | Closed |
|
|
AIM
109
Assured Investment Management
New York
| – | -$119K | -6,126 | Closed |
|
110
SG Americas Securities
New York
| – | -$112K | -5,762 | Closed |
|
|
QT
111
Quantamental Technologies
White Plains,
New York
| – | -$5K | -274 | Closed |
|
|
PHK
112
Point72 Hong Kong
Hong Kong
| – | -$3K | -137 | Closed |
|
APLS Hedge Fund Activity: Q2 2019 in Review
99 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q2 2019, worth a combined $1.03B — up 31% from $782M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new APLS positions and 13 closed out — a net gain of 9 holders — while 47 added to existing stakes and 20 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $25.8M. The largest seller was Morgan Stanley, cutting an estimated $25.2M.
- 99 institutional investors held Apellis Pharmaceuticals (APLS) as of Q2 2019, up from 92 in Q1 2019.
- Funds reported $1.03B of Apellis Pharmaceuticals stock for Q2 2019, up 31% quarter-over-quarter.
- 22 funds opened new Apellis Pharmaceuticals positions in Q2 2019 and 13 closed out, a net change of +9 holders.
- The largest Apellis Pharmaceuticals buyer in Q2 2019 was Wellington Management Group, an estimated $25.8M added.
- The largest Apellis Pharmaceuticals seller in Q2 2019 was Morgan Stanley, an estimated $25.2M sold.
Based on aggregated 13F filings for Q2 2019.